28404899|t|BALB/c mice immunized with a combination of virus-like particles incorporating Kaposi sarcoma-associated herpesvirus (KSHV) envelope glycoproteins gpK8.1, gB, and gH / gL induced comparable serum neutralizing antibody activity to UV - inactivated KSHV
28404899|a|Infection with Kaposi sarcoma-associated herpesvirus (KSHV) is estimated to account for over 44,000 new cases of Kaposi sarcoma annually, with 84% occurring in Africa, where the virus is endemic. To date, there is no prophylactic vaccine against KSHV. KSHV gpK8.1, gB, and gH / gL glycoproteins, implicated in the virus entry into host cells, are attractive vaccine targets for eliciting potent neutralizing antibodies (nAbs) against virus infection. We incorporated gpK8.1, gB, or gH / gL on the surface of virus-like particles (VLPs) and characterized these VLPs for their composition, size, and functionality. To determine which viral glycoprotein(s) elicit the most effective serum - nAbs, we immunized BALB/c mice with gpK8.1, gB, or gH / gL VLPs individually or in combination. Neutralizing antibody assay revealed that sera from mice immunized with the VLPs inhibited KSHV infection of HEK-293 cells in a dose-dependent manner. As a single immunogen, gpK8.1 VLPs stimulated comparable nAb activity to that of UV - inactivated KSHV (UV-KSHV). In contrast, UV-KSHV stimulated higher titers of nAb compared to gB (p = 0.0316) or gH / gL (p = 0.0486). Mice immunized with the combination of gB and gH / gL VLPs had a better nAb response than those immunized with either gB (p = 0.0268), or gH /gL (p = 0.0397) as single VLP immunogens. Immunization with any VLP combination stimulated comparable nAb activity to UV-KSHV serum. Our data provide the first evidence that KSHV gpK8.1, gB, and gH / gL glycoproteins can be incorporated onto the surface of VLPs and used as prophylactic vaccine candidates, with potential to prevent KSHV infection.
28404899	0	11	BALB/c mice	T015	C0025919
28404899	12	21	immunized	T061	C0020971
28404899	44	64	virus-like particles	T026	C0333785
28404899	79	116	Kaposi sarcoma-associated herpesvirus	T005	C0376526
28404899	118	122	KSHV	T005	C0376526
28404899	133	153	glycoproteins gpK8.1	T116	C0767120
28404899	155	157	gB	T116	C0761135
28404899	163	165	gH	T116,T123	C1142879
28404899	168	170	gL	T116,T123	C2606403
28404899	190	195	serum	T031	C0229671
28404899	196	217	neutralizing antibody	T116,T129	C0475463
28404899	218	226	activity	T044	C1621287
28404899	230	232	UV	T070	C0041625
28404899	235	246	inactivated	T169	C0544461
28404899	247	251	KSHV	T005	C0376526
28404899	267	304	Kaposi sarcoma-associated herpesvirus	T005	C0376526
28404899	306	310	KSHV	T005	C0376526
28404899	365	379	Kaposi sarcoma	T191	C0036220
28404899	412	418	Africa	T083	C0001737
28404899	430	435	virus	T005	C0376526
28404899	469	489	prophylactic vaccine	T121,T129	C0042210
28404899	498	502	KSHV	T005	C0376526
28404899	504	508	KSHV	T005	C0376526
28404899	509	515	gpK8.1	T116	C0767120
28404899	517	519	gB	T116	C0761135
28404899	525	527	gH	T116,T123	C1142879
28404899	530	546	gL glycoproteins	T116,T123	C2606403
28404899	566	571	virus	T005	C0376526
28404899	583	593	host cells	T026	C1819995
28404899	610	617	vaccine	T121,T129	C0042210
28404899	618	625	targets	T169	C1521840
28404899	647	670	neutralizing antibodies	T116,T129	C0475463
28404899	672	676	nAbs	T116,T129	C0475463
28404899	686	701	virus infection	T047	C0042769
28404899	719	725	gpK8.1	T116	C0767120
28404899	727	729	gB	T116	C0761135
28404899	727	729	gB	T116	C0761135
28404899	734	736	gH	T116,T123	C1142879
28404899	739	741	gL	T116,T123	C2606403
28404899	760	780	virus-like particles	T026	C0333785
28404899	782	786	VLPs	T026	C0333785
28404899	812	816	VLPs	T026	C0333785
28404899	884	905	viral glycoprotein(s)	T026	C1325834
28404899	932	937	serum	T031	C0229671
28404899	940	944	nAbs	T116,T129	C0475463
28404899	949	958	immunized	T061	C0020971
28404899	959	970	BALB/c mice	T015	C0025919
28404899	976	982	gpK8.1	T116	C0767120
28404899	984	986	gB	T116	C0761135
28404899	991	993	gH	T116,T123	C1142879
28404899	996	998	gL	T116,T123	C2606403
28404899	999	1003	VLPs	T026	C0333785
28404899	1036	1057	Neutralizing antibody	T116,T129	C0475463
28404899	1088	1092	mice	T015	C0025919
28404899	1093	1102	immunized	T061	C0020971
28404899	1112	1116	VLPs	T026	C0333785
28404899	1127	1131	KSHV	T005	C0376526
28404899	1132	1141	infection	T047	C0042769
28404899	1145	1158	HEK-293 cells	T025	C2936239
28404899	1164	1178	dose-dependent	T081	C1512045
28404899	1199	1208	immunogen	T129	C0003320
28404899	1210	1216	gpK8.1	T116	C0767120
28404899	1217	1221	VLPs	T026	C0333785
28404899	1244	1247	nAb	T116,T129	C0475463
28404899	1268	1270	UV	T070	C0041625
28404899	1273	1284	inactivated	T169	C0544461
28404899	1285	1289	KSHV	T005	C0376526
28404899	1291	1298	UV-KSHV	T005	C0376526
28404899	1314	1321	UV-KSHV	T005	C0376526
28404899	1366	1368	gB	T116	C0761135
28404899	1385	1387	gH	T116,T123	C1142879
28404899	1390	1392	gL	T116,T123	C2606403
28404899	1407	1411	Mice	T015	C0025919
28404899	1412	1421	immunized	T061	C0020971
28404899	1446	1448	gB	T116	C0761135
28404899	1453	1455	gH	T116,T123	C1142879
28404899	1458	1460	gL	T116,T123	C2606403
28404899	1461	1465	VLPs	T026	C0333785
28404899	1503	1512	immunized	T061	C0020971
28404899	1525	1527	gB	T116	C0761135
28404899	1545	1547	gH	T116,T123	C1142879
28404899	1575	1578	VLP	T026	C1325725
28404899	1579	1589	immunogens	T129	C0003320
28404899	1591	1603	Immunization	T061	C0020971
28404899	1613	1616	VLP	T026	C1325725
28404899	1651	1654	nAb	T116,T129	C0475463
28404899	1667	1674	UV-KSHV	T005	C0376526
28404899	1675	1680	serum	T031	C0229671
28404899	1723	1727	KSHV	T005	C0376526
28404899	1728	1734	gpK8.1	T116	C0767120
28404899	1736	1738	gB	T116	C0761135
28404899	1744	1746	gH	T116,T123	C1142879
28404899	1749	1765	gL glycoproteins	T116,T123	C2606403
28404899	1806	1810	VLPs	T026	C0333785
28404899	1823	1843	prophylactic vaccine	T121,T129	C0042210
28404899	1882	1886	KSHV	T005	C0376526
28404899	1887	1896	infection	T047	C0042769